SHL Medical

Startseite
Schweiz
Zug
SHL Medical

SHL Medical is a pioneering leader in advanced self-injection solutions such as autoinjectors and pen injectors.

SHL Medical is a pioneering leader in self-injection solutions, such as autoinjectors. Headquartered in Switzerland with sites across three continents, we offer end-to-end services, from design and development to final assembly, labeling, and packaging, partnering with pharma companies to deliver self-injection systems that enable patients’ independence. View SHL Medical trademarks: https://www.shl-medical.com/trademarks

06/04/2026

Treating retinopathy of prematurity (ROP) often involves intravitreal injections at the microliter scale.

ROP affects premature infants and can lead to abnormal retinal blood vessel development. The condition progresses through defined stages (Stages 1–5), from mild retinal changes to total retinal detachment. In severe cases, this may result in vision loss.

For infants requiring treatment, doses are typically administered at around 10 µL per eye. Technologies such as SHL Medical’s Micro Dosing Device (MDD) support applications that require reliable low-volume dosing.

👉 Explore microliter-scale dosing in ROP: https://bit.ly/3PHDRJi

03/04/2026

We shared a glimpse of life at SHL Medical with representatives from the Swedish Chamber of Commerce Taipei (SCCT) and the Swiss-Taiwan Business Alliance during their visits to our Taiwan site.

From a tour of our fully automated manufacturing facilities to a shared meal at the cafeteria, the visits offered a firsthand look at the culture and environment that shape our workplace.

Guests showed particular interest in how colleagues from different cultural and professional backgrounds collaborate across global functions. Several visitors were also surprised by the well-maintained and spacious facility, which led to conversations about SHL Medical’s long-term presence and continued growth in Taiwan.

As we continue to expand globally, interactions like these help us stay connected with the local business community and better understand regional developments.

Thank you Pojanath Chao, Executive Director of SCCT, and Sebastian Blaettler, Board Member of the Swiss-Taiwan Business Alliance, for your visits. We look forward to exploring future opportunities for collaboration.

02/04/2026

In cardiometabolic therapies, moving from clinical supply to global commercialization depends on more than device design.

The challenge often shifts from demonstrating performance to delivering it reliably at scale.

Supported by SHL Medical’s global, multi-site manufacturing network and alliance ecosystem, Quanta reflects an approach built for consistent delivery from pilot production through large-scale commercialization.

01/04/2026

Day 2 at has brought deeper conversations around self-injection development in APAC and beyond.

Alongside our device platforms and development services, many discussions have centered on industrialization strategies across the device program lifecycle.

Our SHL Advantec colleagues are on site sharing how market-proven tooling and automation solutions support program industrialization.

We’ll be at Booth for the next two days and happy to exchange perspectives.

31/03/2026

A strong first day at , with meaningful discussions around lyophilized drug delivery and how pen injectors are evolving for cardiometabolic therapies.

Many conversations around Quanta focused on its multi-fixed-dose approach and no-priming design, which are increasingly important as therapies move into long-term use for larger populations.

We’re on site through April 3. If you’re attending, stop by Booth to explore our device portfolio in person.

30/03/2026

In neonatal ophthalmology, some treatments involve doses as small as 10 µL per eye.

In the latest issue of ONdrugDelivery, SHL Medical’s Samuel Wyler and Seda Aksel, PhD, together with Bayer’s Andreas Kalitzki, examine precision considerations for intravitreal injection in the treatment of retinopathy of prematurity.

The article discusses how device design can help address variability in low-volume injections and presents a pediatric dosing device based on SHL Medical’s Micro Dosing Device technology.

👉 Read the full article: https://bit.ly/3PHDRJi

27/03/2026

At 2026, discussions centered on how early alignment across partners influences the trajectory of combination product programs.

Across the week, our teams engaged with partners on how these programs progress from development to commercial scale, where ex*****on depends on how effectively device design, manufacturing, and supply are coordinated. SHL Medical supports this through integrated capabilities and collaboration models designed for long-term continuity.

With over 1.5 billion devices used by patients worldwide, our focus remains on helping partners reduce risk, advance programs with greater certainty, and deliver at scale.

We look forward to continuing the discussion at PFS East Coast in Boston.

26/03/2026

How can primary containers and delivery systems be effectively aligned as biologics formulations and delivery requirements continue to evolve?

On April 16, SHL Medical’s Dr. Nina Fetz will join Michelle Roos of SCHOTT Pharma in a live Pharmaversity® webinar to discuss cartridge-based delivery systems and the integration of the SCHOTT TOPPAC® polymer cartridge with SHL Medical’s Maggie large-volume cartridge autoinjector.

Their joint session will explore key considerations in integrating cartridge and autoinjector platforms, including polymer cartridge design and manufacturing, mechanical compatibility, and pre-verified cartridge–device performance data to support early-stage development.

Join the webinar to learn more about cartridge–device integration for large-volume subcutaneous delivery: https://bit.ly/4swktOb

25/03/2026

Collaboration between SHL Medical and Thermo Fisher Scientific creates a unique end-to-end offering for combination products.

With SHL Medical’s device platforms and development expertise, along with Thermo Fisher’s state-of-the-art sterile fill-finish and packaging capabilities and new final assembly line at Ridgefield, NJ site for our Molly autoinjectors, we can support customers with a more integrated pathway from drug product through final assembly and packaging.

The collaboration further strengthens SHL Medical’s presence in the US. With device manufacturing capabilities at our North Charleston site and final assembly, labeling, and packaging services at our Deerfield Beach site, we’re committed to enhancing supply resilience within the US market.

Together with Thermo Fisher Scientific, we continue to strengthen the ecosystem that enables pharma companies to bring combination products to patients with reliability, scale, and speed.

24/03/2026

From Taiwan to South Carolina, Aerolle Mitra stepped into a site that was still taking shape. The move wasn't just a cultural shift; it meant going from a mature manufacturing environment to one without an established playbook. Processes were still evolving, teams were forming, and many ways of working had yet to be defined. For Aerolle, that uncertainty became the opportunity to build.

Working side by side with technicians, engineers, and leaders, he not only established the Continuous Improvement team from scratch, but shaped how Continuous Improvement lives on the shop floor. This led to more structured processes, stronger collaboration across levels, and teams confidently taking ownership of improving how work gets done.

His efforts are strongly grounded in his belief that the most meaningful results come from small, consistent improvements driven by the people closest to the work. His passion lies in creating an environment where improvement is part of everyday thinking, not just a program.

This is what growth at SHL Medical looks like: The chance to create, not just operate, surrounded by a culture that values curiosity, embraces change, and empowers ownership by solving real problems in a constantly evolving environment.

23/03/2026

Device design influences program economics long before commercialization begins.

Early platform decisions affect fill-and-finish efficiency, packaging configuration, and long-term supply scalability. Together, these factors determine total cost of ownership years later.

By consolidating multiple doses into a single primary container, Quanta’s multi-dose format reduces packaging complexity and improves manufacturing efficiency and cold-chain logistics at scale.

20/03/2026

“Give to Gain,” this year’s International Women’s Day theme, reflects a simple idea: confidence grows when it is shared.

At SHL Medical, that idea came to life through conversations across our global teams.

In Taiwan, Lucy Chung, General Manager of SHL Advantec, Dora Rio, Head of Sustainability, and Penny Liao, Senior HR Director, shared key moments from their careers, including challenges they faced and turning points that strengthened their confidence. Their stories sparked open discussions among colleagues about what it takes to grow in confidence.

Similar conversations unfolded in the US, where Maria Williams, Senior Manager, Quality Engineering, shared perspectives on women’s health and encouraged colleagues to reflect on how caring for our well-being strengthens resilience and shapes the way we lead and support others.

In Sweden, the dialogue extended to the next generation as students joined Introduce a Girl to Engineering Day, taking part in hands-on activities and learning how our engineers began their careers.

Confidence grows when experiences are shared and organizations create space for people to support one another’s growth.

Adresse

Gubelstrasse 22
Zug
6300

Webseite

http://www.shl-medical.com/, https://www.shl-medical.com/trademarks

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von SHL Medical erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Die Praxis Kontaktieren

Nachricht an SHL Medical senden:

Verknüpfungen

Wollen Sie Ihr Praxis zum Top-Klinik in Zug machen?

Our Story

SHL Medical is a world-leading provider of drug delivery solutions. We design, develop, and manufacture advanced drug delivery devices such as autoinjectors, pen injectors, and wearable drug delivery systems. We also offer design-to-build and contract manufacturing services for products such as laboratory handling equipment, neurosurgical devices, and industrial equipment.

By integrating our experienced development teams with efficient manufacturing and a skilled workforce, we have developed a successful business model that allows us to provide comprehensive solutions for demanding requirements of the industry. As the largest company in SHL Group, SHL Medical continues to offer experience, excellence, and vision to customers and partners all over the world.